Quickstatus
Enthusiast
- Joined
- Oct 13, 2013
- Posts
- 18,967
@prozac
It appears Xanamem is undergoing Phase 2 trials
There is still a long way to go
The big Phase 3 trial - where they test it on thousands of people is yet to be undertaken
There is another AD trial drug called Lecanemab (an antibody against the amyloid) which took, I think 5 years, for Phase 3. It is now approved by the TGA but not by the PBS meaning it costs about $40K a year.
Typically a Phase 3 might take 3-5 years, then 1 year for TGA approval and another year for PBS approval for concessional pricing.
Based on a quick look Specifically for Xanamem, it appears that the data suggest that while it has a eexcellent safety profile, it did not reach statistical significance for the study primary endpoint for the overall study population
. However in the older group >75yrs, there appears to be a slight benefit - a statistically significant 40% did not show disease progression compared with 22% in placebo. Other small benefits were not statistically significant.
They could do a larger study to get more statistical power for a longer period. 9 months is not very long to study Alzheimer treatment.
Consequently The phase 3 trial has been suspended and funding for it apparently withdrawn, and they may or may not be doing one for that older cohort.
It appears Xanamem is undergoing Phase 2 trials
There is still a long way to go
The big Phase 3 trial - where they test it on thousands of people is yet to be undertaken
There is another AD trial drug called Lecanemab (an antibody against the amyloid) which took, I think 5 years, for Phase 3. It is now approved by the TGA but not by the PBS meaning it costs about $40K a year.
Typically a Phase 3 might take 3-5 years, then 1 year for TGA approval and another year for PBS approval for concessional pricing.
Based on a quick look Specifically for Xanamem, it appears that the data suggest that while it has a eexcellent safety profile, it did not reach statistical significance for the study primary endpoint for the overall study population
. However in the older group >75yrs, there appears to be a slight benefit - a statistically significant 40% did not show disease progression compared with 22% in placebo. Other small benefits were not statistically significant.
They could do a larger study to get more statistical power for a longer period. 9 months is not very long to study Alzheimer treatment.
Consequently The phase 3 trial has been suspended and funding for it apparently withdrawn, and they may or may not be doing one for that older cohort.
Last edited:

